Actively Recruiting
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
Led by Regina Elena Cancer Institute · Updated on 2022-09-28
146
Participants Needed
3
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, open, randomized phase II trial.
CONDITIONS
Official Title
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically proven prostate adenocarcinoma
- Unfavorable intermediate risk or high risk as defined by NCCN
- No lymph node or distant metastases (N0M0) confirmed by choline or preferably PSMA PET-CT
- ECOG performance status between 0 and 2
You will not qualify if you...
- Previous prostate surgery such as radical prostatectomy or cryotherapy
- Previous radiotherapy to the pelvis
- Chemotherapy for any malignancy within the past 5 years
- Inability to implant fiducials for tracking
- Inability to undergo prostate MRI
- Contraindications to short-term androgen deprivation therapy
- Prostate volume greater than 90cc
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Ifo Regina elena
Rome, Lazio, Italy, 00144
Actively Recruiting
2
ifo Regina Elena
Rome, RM, Italy, 00144
Actively Recruiting
3
Regina Elena National Cancer Institute
Rome, Italy, 00144
Actively Recruiting
Research Team
G
Giuseppe Sanguineti, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here